Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA2DS2-VASc and HAS-BLED

American Heart Journal

Volumn 197, Issue , 2018, Pages 27-34

  Rivera Caravaca, José Miguel ^a,b   Roldán, Vanessa ^b   Esteve Pastor, María Asunción ^a,c   Valdés, Mariano ^c   Vicente, Vicente ^b   Marín, Francisco ^c   Lip, Gregory Y H ^a,d  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b HOSPITAL MORALES MESEGUER   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^d AALBORG UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTIVITAMIN K; ANTICOAGULANT AGENT; WARFARIN;

AGED; ALL CAUSE MORTALITY; ANTICOAGULANT THERAPY; APPARENT LIFE THREATENING EVENT; ARTICLE; BLEEDING; CARDIAC PATIENT; CEREBROVASCULAR ACCIDENT; CHA2DS2-VASC SCORE; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK PATIENT; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; TIMI AS SCORE; TREATMENT DURATION; VERY ELDERLY; ADVERSE DRUG REACTION; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; COMPLICATION; INTERNATIONAL NORMALIZED RATIO; METHODOLOGY; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; SPAIN;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; LONG TERM ADVERSE EFFECTS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; SPAIN; STROKE; WARFARIN;

EID: 85040021030     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2017.11.004     Document Type: Article

References (33)

1. Hart, R.G., Pearce, L.A., Aguilar, M.I., Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:12 (2007), 857–867.
2. Chao, T.F., Liu, C.J., Tuan, T.C., et al. Impact on Outcomes of Changing Treatment Guideline Recommendations for Stroke Prevention in Atrial Fibrillation: A Nationwide Cohort Study. Mayo Clin Proc 91:5 (2016), 567–574.
3. Lip, G.Y., Laroche, C., Popescu, M.I., et al. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. Europace 17:12 (2015), 1777–1786.
4. Diez-Manglano, J., Gomes-Martin, J., Al-Cheikh-Felices, P., et al. Adherence to guidelines and mortality in atrial fibrillation. Int J Cardiol 176:2 (2014), 430–436.
5. Ogilvie, I.M., Newton, N., Welner, S.A., et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 123:7 (2010), 638–645.e4.
6. Huisman, M.V., Rothman, K.J., Paquette, M., et al. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2. J Am Coll Cardiol 69:7 (2017), 777–785.
7. Ruff, C.T., Giugliano, R.P., Braunwald, E., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:9921 (2014), 955–962.
8. Macle, L., Cairns, J., Leblanc, K., et al. 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Can J Cardiol 32:10 (2016), 1170–1185.
9. Kirchhof, P., Benussi, S., Kotecha, D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:38 (2016), 2893–2962.
10. Fanola, C.L., Giugliano, R.P., Ruff, C.T., et al. A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. Eur Heart J 38:12 (2017), 888–896.
11. Lip, G.Y.H., Lane, D.A., Buller, H., et al. Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS Study. Chest 144:6 (2013), 1839–1847.
12. Lip, G.Y., Nieuwlaat, R., Pisters, R., et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 137:2 (2010), 263–272.
13. Pisters, R., Lane, D.A., Nieuwlaat, R., et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138:5 (2010), 1093–1100.
14. Schulman, S., Kearon, C., Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:4 (2005), 692–694.
15. DeLong, E.R., DeLong, D.M., Clarke-Pearson, D.L., Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:3 (1988), 837–845.
16. Pencina, M.J., D'Agostino, R.B. Sr., D'Agostino, R.B. Jr., et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27:2 (2008), 157–172 [discussion 207-112].
17. Vickers, A.J., Cronin, A.M., Elkin, E.B., et al. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak, 8, 2008, 53.
18. Vickers, A.J., Elkin, E.B., Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 26:6 (2006), 565–574.
19. Marcucci, M., Lip, G.Y., Nieuwlaat, R., et al. Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey. Am J Med 127:10 (2014), 979–986.e2.
20. Lip, G.Y., Atrial Fibrillation in Patients With Hypertension: Trajectories of Risk Factors in Yet Another Manifestation of Hypertensive Target Organ Damage. Hypertension 68:3 (2016), 544–545.
21. Guo, Y., Wang, H., Tian, Y., et al. Multiple risk factors and ischaemic stroke in the elderly Asian population with and without atrial fibrillation. An analysis of 425,600 Chinese individuals without prior stroke. Thromb Haemost 115:1 (2016), 184–192.
22. Lip, G.Y., Lane, D.A., Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores. J Thromb Haemost 14:9 (2016), 1711–1714.
23. Esteve-Pastor, M.A., Rivera-Caravaca, J.M., Lip, G.Y.H., Hypertension and Atrial Fibrillation: Balancing Stroke and Bleeding Risks. Am J Hypertens 30:11 (2017), 1063–1065.
24. Olesen, J.B., Torp-Pedersen, C., Hansen, M.L., et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost 107:6 (2012), 1172–1179.
25. Nielsen, P.B., Chao, T.F., The risks of risk scores for stroke risk assessment in atrial fibrillation. Thromb Haemost 113:6 (2015), 1170–1173.
26. Olesen, J.B., Torp-Pedersen, C., Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc >/=1, or higher?. Thromb Haemost 113:6 (2015), 1165–1169.
27. Lip, G.Y., Frison, L., Halperin, J.L., et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 57:2 (2011), 173–180.
28. Shahid, F., Shantsila, E., Lip, G.Y.H., What do the guidelines suggest for non-vitamin K antagonist oral anticoagulant use for stroke prevention in atrial fibrillation?. Eur Heart J Suppl 18:Suppl_I (2016), I18–I24.
29. Roldan, I., Marin, F., On the Way to a Better Use of Anticoagulants in Nonvalvular Atrial Fibrillation. Proposed Amendment to the Therapeutic Positioning Report UT/V4/23122013. Rev Esp Cardiol (Engl Ed) 69:6 (2016), 551–553.
30. Diener, H.C., Aisenberg, J., Ansell, J., et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J 38 (2017), 860–868.
31. Freedman, B., Lip, G.Y., “Unreal world” or “real world” data in oral anticoagulant treatment of atrial fibrillation. Thromb Haemost 116:4 (2016), 587–589.
32. Potpara, T.S., Lip, G.Y., Postapproval Observational Studies of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation. JAMA 317:11 (2017), 1115–1116.
33. Garcia, D.A., Lopes, R.D., Hylek, E.M., New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. Thromb Haemost 104:6 (2010), 1099–1105.